Gyre Therapeutics Inc (GYRE)

Apr 30, 2025

GNI Group Confirms NDA Timeline for Hydronidone - TipRanks

Apr 30, 2025

Apr 14, 2025

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Apr 14, 2025

Apr 09, 2025

GYRE Stock Plummets to 52-Week Low at $6.15 Amid Market Challenges - Investing.com Canada

Apr 09, 2025

Apr 02, 2025

Cognyte Software Posts Upbeat Results, Joins AngioDynamics, Allegiant Travel And Other Big Stocks Moving Higher On Wednesday - Benzinga

Apr 02, 2025

Mar 31, 2025

GYRE Stock Hits 52-Week Low at $8.26 Amid Market Challenges - Investing.com UK

Mar 31, 2025

Mar 31, 2025

Gyre Therapeutics Says China's NMPA Approves Pirfenidone Trial in Lung Injury - MarketScreener

Mar 31, 2025

Mar 31, 2025

Gyre Therapeutics announces NMPA approval for trial on pirfenidone - TipRanks

Mar 31, 2025

Mar 31, 2025

Major Breakthrough: Gyre's Cancer Drug Trial Targets 25% of Radiation Therapy Patients - Stock Titan

Mar 31, 2025

Mar 30, 2025

Bank of New York Mellon Corp Has $168,000 Stock Holdings in Gyre Therapeutics, Inc. (NASDAQ:GYRE) - Defense World

Mar 30, 2025

Mar 27, 2025

Gyre Therapeutics announces publication of protocol for Phase 3 trial on F351 - TipRanks

Mar 27, 2025

Mar 27, 2025

We Think You Should Be Aware Of Some Concerning Factors In Gyre Therapeutics' (NASDAQ:GYRE) Earnings - Yahoo Finance

Mar 27, 2025

Mar 27, 2025

Major Breakthrough: New Phase 3 Trial Targets Chronic Hepatitis B Liver Fibrosis Treatment - Stock Titan

Mar 27, 2025

Mar 25, 2025

Gyre therapeutics president Ma Songjiang sells common stock for $1,740 By Investing.com - Investing.com Canada

Mar 25, 2025

Mar 25, 2025

Gyre therapeutics president Ma Songjiang sells common stock for $1,740 - Investing.com Australia

Mar 25, 2025

Mar 23, 2025

Gyre Therapeutics (NASDAQ:GYRE) Trading Down 4.7% – Here’s Why - Defense World

Mar 23, 2025

Mar 22, 2025

Gyre therapeutics president Ma Songjiang sells $40,440 in stock By Investing.com - Investing.com Canada

Mar 22, 2025

Mar 21, 2025

Gyre therapeutics president Ma Songjiang sells $40,440 in stock - Investing.com India

Mar 21, 2025

Mar 21, 2025

GyreIntriguing Upcoming Data Catalyst, But I'm Still On Sidelines (NASDAQ:GYRE) - Seeking Alpha

Mar 21, 2025

Mar 21, 2025

Gyre Therapeutics Reports Strong Turnaround in 2024 Earnings - TipRanks

Mar 21, 2025

Mar 19, 2025

Gyre Therapeutics president Ma Songjiang sells $26,658 in stock - Investing.com

Mar 19, 2025

Mar 19, 2025

Gyre Therapeutics president Ma Songjiang sells $26,658 in stock By Investing.com - Investing.com South Africa

Mar 19, 2025

Mar 19, 2025

Gyre Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Mar 19, 2025

Mar 19, 2025

Gyre Therapeutics Inc (GYRE) Q4 2024 Earnings: Revenue Surpasses Estimates at $27.9M, EPS Misses at $0.00 - GuruFocus.com

Mar 19, 2025

Mar 19, 2025

Impact of New U.S. Regulations on Gyre Therapeutics: Potential Delisting Risks and Investor Concerns - TipRanks

Mar 19, 2025

Mar 19, 2025

Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Down on Disappointing Earnings - Defense World

Mar 19, 2025

Mar 18, 2025

S&P 500 Down 1%; Sarepta Therapeutics Shares Plunge - Benzinga

Mar 18, 2025

Mar 18, 2025

12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga

Mar 18, 2025

Mar 18, 2025

Gyre Therapeutics (GYRE) Projected to Post Earnings on Tuesday - Defense World

Mar 18, 2025

Mar 18, 2025

Decoding Gyre Therapeutics Inc (GYRE): A Strategic SWOT Insight - GuruFocus

Mar 18, 2025

Mar 17, 2025

Gyre Therapeutics offers weak 2025 revenue guidance - Investing.com India

Mar 17, 2025

Mar 17, 2025

Gyre Therapeutics offers weak 2025 revenue guidance By Investing.com - Investing.com Canada

Mar 17, 2025

Mar 17, 2025

Gyre Therapeutics Reports Breakeven in Q4 as Revenue Increases -March 17, 2025 at 04:52 pm EDT - Marketscreener.com

Mar 17, 2025

Mar 17, 2025

Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times

Mar 17, 2025

Mar 17, 2025

(GYRE) Gyre Therapeutics Sees 2025 Revenue Range $118M$128M -March 17, 2025 at 04:18 pm EDT - Marketscreener.com

Mar 17, 2025

Mar 14, 2025

FY2024 Earnings Forecast for GYRE Issued By Noble Financial - Defense World

Mar 14, 2025

Mar 14, 2025

Gyre Therapeutics president Ma Songjiang sells $46,280 in stock By Investing.com - Investing.com Canada

Mar 14, 2025

Mar 13, 2025

Gyre Therapeutics president Ma Songjiang sells $46,280 in stock - Investing.com India

Mar 13, 2025

Mar 13, 2025

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

Mar 13, 2025

Mar 12, 2025

Exploring High Growth Tech Stocks In The US March 2025 - Simply Wall St

Mar 12, 2025

Mar 12, 2025

Gyre therapeutics president Ma Songjiang sells $40,776 in stock By Investing.com - Investing.com South Africa

Mar 12, 2025

Mar 12, 2025

Gyre Therapeutics (NASDAQ:GYRE) Coverage Initiated by Analysts at Noble Financial - Defense World

Mar 12, 2025

Mar 11, 2025

Gyre therapeutics president Ma Songjiang sells $40,776 in stock - Investing.com

Mar 11, 2025

Mar 11, 2025

Noble Capital Initiates Coverage on Gyre Therapeutics With Outperform Rating, $20 Price Target - Marketscreener.com

Mar 11, 2025

Mar 11, 2025

Gyre Therapeutics initiated with an Outperform at Noble Capital - TipRanks

Mar 11, 2025

Mar 09, 2025

Gyre Therapeutics president Ma Songjiang sells $42,480 in stock - MSN

Mar 09, 2025